Prostate Cancer Treatment in China for International Patients
China offers the full spectrum of prostate-cancer care, including active surveillance, radical prostatectomy, external-beam radiation, brachytherapy, hormone-based systemic treatment, chemotherapy, particle therapy and advanced PSMA-based treatment. HIFU is also used in prostate cancer, but it is a selected focal or whole-gland approach rather than a universal replacement for surgery or radiation.
Quick answer: the first decision is not “Which Chinese hospital?” It is
localized vs locally advanced vs metastatic disease, risk group, Grade Group, PSA, MRI/PSMA staging and
previous treatment. A patient with low-risk localized cancer may need surveillance rather than travel,
while a patient with high-risk disease, recurrence or metastatic castration-resistant prostate cancer may need a
completely different center and technology.
✓ Risk-group first
✓ HIFU claims checked carefully
✓ Standard care compared before travel
✓ No guaranteed outcome
What Decides Prostate Cancer Treatment Before You Choose China?
“Prostate cancer” is not one treatment pathway. The same PSA value can mean very different things depending on MRI, biopsy grade, stage, prostate anatomy, age, symptoms and previous treatment.
Biopsy pathology and Gleason/Grade Group help estimate aggressiveness and are central to treatment selection.
PSA trend, multiparametric MRI and appropriate metastatic staging help distinguish localized from more extensive disease.
Untreated localized cancer, recurrence after radiation and progression after hormone therapy are different clinical problems.
Urinary symptoms, sexual function, cardiovascular risk, frailty and treatment priorities change the risk-benefit balance.
Prostate Cancer in China: Why This Treatment Market Is Growing
China is treating a growing prostate-cancer burden. A 2026 Fudan University Shanghai Medical College
report, citing National Cancer Center 2024 data, states that China recorded about 134,000 new prostate-cancer
cases in 2022. Chinese cancer centers are expanding prostate surgery, precision imaging, advanced radiation,
systemic therapy and PSMA-based treatment.
For an international patient, incidence statistics are background—not a reason to choose a hospital. The useful question is whether a Chinese center offers a disease-specific pathway that improves the decision you already face: surgery vs radiation, focal therapy, salvage treatment, metastatic systemic treatment or a later-line option.
Prostate Cancer Treatment in China by Stage and Risk Group
| Clinical situation | Common treatment questions | China-specific reason to travel | What must be confirmed first |
|---|---|---|---|
| Low-risk localized disease | Active surveillance vs definitive local treatment. | Usually weak unless the diagnosis/risk group is uncertain or a specific focal-treatment review is sought. | Biopsy Grade Group, MRI lesion, PSA density, life expectancy and surveillance feasibility. |
| Intermediate-risk localized disease | Surgery, modern external-beam radiation, brachytherapy; focal therapy only in selected settings. | Expert robotic-surgery review, radiation comparison, HIFU/focal-therapy evaluation or particle-therapy question. | Favorable vs unfavorable risk, urinary function, MRI, prostate volume/anatomy, biopsy distribution. |
| High-risk / locally advanced disease | Multimodal therapy: surgery in selected patients or radiation plus systemic treatment. | Disease-specific MDT, complex surgery/radiation planning, staging or second opinion. | Node/metastatic staging, local extension, Grade Group, PSA, fitness and systemic-treatment plan. |
| Metastatic hormone-sensitive disease | ADT plus additional systemic therapy; selected patients may also have a role for prostate-directed radiation. | Complex systemic-treatment sequencing, imaging, molecular testing or a clinical-trial question. | Metastatic burden, symptoms, previous drugs, comorbidities, molecular/genetic findings. |
| Biochemical / local recurrence | Locate recurrence, then consider salvage radiation, surgery or selected local salvage approaches. | PSMA PET/CT, salvage-treatment review or specialized radiation/ablation question. | Original treatment, PSA kinetics, MRI/PSMA PET, biopsy when needed and evidence of distant disease. |
| Metastatic castration-resistant prostate cancer (mCRPC) | Sequence systemic treatments; assess PSMA-targeted radioligand therapy, targeted treatment or trials when appropriate. | 2026 PSMA radioligand pathway at selected Shanghai centers, advanced imaging or later-line treatment review. | Prior ADT/ARPI/chemotherapy, current testosterone, PSMA expression, marrow/kidney function, molecular testing. |
Can Prostate Cancer Be Cured in China?
Localized prostate cancer is often treated with curative intent, but “cure in China” is not a treatment
category. The relevant comparison is whether the patient can reasonably achieve durable cancer control with
surveillance, surgery or radiation—and what urinary, bowel and sexual side effects come with each choice.
Localized disease
Active surveillance, radical prostatectomy and radiation are established pathways; selection depends on risk and patient factors.
Locally advanced disease
Curative-intent treatment may still be possible, but combined local and systemic treatment is often considered.
Metastatic disease
The goal is usually long-term disease control, symptom prevention and survival rather than a guaranteed cure.
HIFU for Prostate Cancer in China
High-intensity focused ultrasound (HIFU) uses concentrated ultrasound energy to heat and destroy targeted prostate tissue. Chinese prostate-cancer guidance discusses HIFU as a prostate-cancer treatment option, including primary localized treatment and selected salvage use after radiotherapy.
HIFU is not automatically “better because it is minimally invasive.” Current 2026 European guidance
remains cautious and recommends whole-gland or focal ablative therapy such as HIFU mainly within clinical trials or
registries because long-term comparative cancer-control evidence remains less mature than for surgery or radiation.
When HIFU may be worth discussing
- Localized disease with a clearly defined target
- Patient understands standard active-surveillance/surgery/radiation options
- MRI and biopsy mapping are adequate for focal planning
- Functional preservation is an important treatment priority
- Selected local recurrence after prior radiotherapy
When HIFU should not drive the referral
- High-risk or locally advanced disease without a standard-treatment review
- Known metastatic disease where a prostate-only ablation will not treat systemic cancer
- Incomplete biopsy or MRI staging
- A clinic sells “HIFU cure” without stating focal vs whole-gland treatment
- No plan for PSA, MRI and repeat-biopsy follow-up
Which Hospitals in China Use HIFU for Prostate Cancer?
HIFU appears in Chinese prostate-cancer guidance, but hospital availability changes and public international-service pages do not provide one reliable nationwide list of foreign-patient HIFU programs. For that reason, Parkmega does not publish a “top HIFU hospitals” list based only on marketing pages.
Before traveling for HIFU, get six answers in writing: hospital and department; HIFU device/model;
focal vs whole-gland treatment; MRI/biopsy eligibility criteria; whether the case is routine care, registry or study;
and the required post-treatment MRI/PSA/biopsy schedule.
If a named Chinese hospital has already offered HIFU, send us the proposal and records. We can compare the stated indication with standard surgery/radiation options and ask the hospital to clarify the pathway.
Radical Prostatectomy and Robotic Surgery in China
Radical prostatectomy remains a standard curative-intent option for selected localized and locally advanced prostate cancer. Large Chinese urologic-oncology centers perform laparoscopic and robotic prostatectomy, including nerve-sparing approaches in appropriately selected patients.
What surgery removes
The prostate and seminal vesicles are removed; pelvic lymph-node assessment may be added according to risk.
What “robotic” does not mean
A robot is a surgical platform, not proof of better cancer control. Surgeon/team experience and appropriate selection still matter.
Key trade-offs
Urinary continence, erectile function, margin risk, lymph-node risk, recovery time and possible later radiation should be discussed before travel.
Radiation Therapy: External Beam, Brachytherapy and Particle Therapy
IMRT / VMAT / SBRT
- Established curative-intent radiation options
- Risk group determines whether ADT is added
- Modern image guidance matters
- Compare fractionation and side-effect plan
Brachytherapy
- Radioactive sources placed in/near prostate
- Can be definitive or a radiation boost
- Urinary function and anatomy affect suitability
- Seed implantation is available at selected China centers
Proton / Heavy Ion
- Available at Shanghai Proton and Heavy Ion Center
- International-patient route is published
- Prostate cancer is among treated tumor types
- Ask for benefit vs modern photon radiotherapy
Related: Proton Therapy in China.
Metastatic Prostate Cancer: Systemic Treatment Comes First
Once prostate cancer has spread beyond the prostate, treatment decisions shift from a local procedure to systemic disease control. Androgen-deprivation therapy (ADT) remains a foundation, but modern metastatic hormone-sensitive treatment commonly intensifies ADT with another systemic treatment rather than relying on ADT alone.
Hormone-sensitive metastatic disease
- ADT as treatment foundation
- Androgen-receptor pathway inhibitor according to the clinical scenario
- Docetaxel in selected patients
- Selected cases may need prostate-directed radiation
- Bone health and symptom management
What determines the sequence
- Disease volume and location
- Symptoms and performance status
- Previous drugs and response duration
- Cardiovascular/metabolic comorbidity
- Genetic and molecular findings
Castration-Resistant Prostate Cancer (CRPC) in China
Castration-resistant prostate cancer means the cancer is progressing despite castrate-level testosterone. The next treatment depends on whether disease is metastatic, which hormone-pathway drugs and chemotherapy were already used, molecular findings, PSMA expression, symptoms and organ/bone-marrow function.
Important 2026 China development: Fudan University Shanghai Cancer Center reported clinical rollout
of Lu-177-PSMA radioligand therapy for selected PSMA-positive metastatic castration-resistant
prostate cancer after prior treatment. The pathway uses PSMA imaging and multidisciplinary assessment; it is not
appropriate for every CRPC patient.
Re-stage first
Confirm progression, testosterone level, PSMA imaging when relevant, disease distribution and symptoms.
Review prior lines
AR-pathway drugs, docetaxel/cabazitaxel and previous radiation affect the next treatment decision.
Check biomarkers
Selected genomic findings can change eligibility for targeted treatment or a clinical trial.
Hospitals in China to Consider for Prostate Cancer
The best hospital depends on the medical question. A center that is strong in robotic surgery is not automatically the best place for particle therapy, HIFU, salvage treatment or PSMA radioligand therapy.
| Center | Why it may fit | International-access note | Best question to ask |
|---|---|---|---|
| Fudan University Shanghai Cancer Center (FUSCC) | Disease-specific urologic oncology, prostate MDT, surgery, PSMA imaging/research and 2026 Lu-177-PSMA radioligand pathway. | Medical strength is clear; direct overseas self-pay access should be reconfirmed before travel. | What is the best prostate-cancer pathway for this risk/stage, and is PSMA-based treatment relevant? |
| Shanghai Proton and Heavy Ion Center | Dedicated proton/heavy-ion radiation center; prostate cancer is among its treated tumor types. | Shanghai Government publishes international service, English/Japanese/German and contact details. | What advantage does particle therapy offer this patient over modern photon radiation? |
| National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences | Dedicated urologic-oncology department treating prostate cancer with robotic/laparoscopic surgery, MDT and advanced-disease treatment. | Beijing appointment infrastructure exists; confirm the practical overseas route for the exact department. | Is surgery appropriate, and what nerve-sparing/lymph-node plan applies? |
| Guangzhou Fuda Cancer Hospital | International cancer hospital with iodine-125 brachytherapy and selected local/interventional options. | Foreign-patient contacts are public and established. | Why is brachytherapy/local treatment preferred to standard prostate surgery or external-beam radiation for this exact case? |
No one hospital should be the default for every prostate-cancer patient. For localized disease,
compare standard curative options first. For mCRPC, a PSMA/nuclear-medicine center may matter more. For particle
therapy, use a particle center. For a focal/HIFU proposal, verify the exact program rather than choosing by hospital
brand alone.
Related: Best Cancer Hospitals in China · Hospitals in Shanghai · Hospitals in Beijing · Fuda Cancer Hospital Guangzhou.
How to Match the Hospital to the Prostate Cancer Question
Surgery vs Radiation
- Compare standard curative options
- Ask about continence and sexual-function trade-offs
- Review nerve-sparing and radiation dose/fractionation
HIFU / Ablation
- Verify MRI/biopsy target
- Ask whether treatment is focal or whole-gland
- Demand follow-up biopsy plan
PSMA / Systemic Therapy
- Review previous drug sequence
- Check PSMA expression and molecular tests
- Use disease-specific medical oncology/nuclear medicine
How Much Does Prostate Cancer Treatment Cost in China?
There is no reliable one-price answer. Cost depends on whether the patient needs only a specialist
review and staging, a robotic operation, several weeks of radiation, brachytherapy, particle therapy, long-term
systemic medication or a later-line radiopharmaceutical pathway.
Diagnosis and staging
Pathology review, MRI, PSMA PET/CT, laboratory testing and additional biopsy can materially change the estimate.
Definitive local treatment
Surgery, external-beam radiation, brachytherapy, HIFU and particle therapy use different resources and timelines.
Advanced systemic treatment
Long-term drug therapy, chemotherapy, targeted treatment and radioligand therapy can dominate total cost.
Ask for a written estimate after record review. The estimate should identify hospital/department, planned tests, procedure or drugs, inpatient days, follow-up, interpreter/international service fees and what happens if the plan changes after staging.
Related: Cancer Treatment Cost in China.
What Medical Records Should You Send?
Minimum prostate-cancer file
- Age and major medical conditions
- PSA values with dates, not only the latest number
- Biopsy pathology with Gleason score / Grade Group
- Multiparametric prostate MRI report and DICOM files
- CT / bone scan / PSMA PET if already performed
- Current urinary symptoms and medication
- The exact decision you want a Chinese team to answer
If treatment has already started
- Previous prostate surgery or radiotherapy records
- ADT start date and current testosterone if relevant
- Abiraterone / enzalutamide / apalutamide / darolutamide history as applicable
- Chemotherapy names, dates and response
- Genomic / germline / tumor molecular testing
- Current blood count, kidney and liver function
- Any hospital proposal already received from China
When Not to Fly to China for Prostate Cancer Treatment
The older version of this Parkmega guide emphasized travel safety. That remains important: international travel is useful only when the patient is stable and the receiving hospital has a real clinical question to answer.
Seek urgent local medical care rather than waiting for travel if there is acute urinary retention,
uncontrolled bleeding, severe uncontrolled pain, new leg weakness or numbness, loss of bladder/bowel control,
suspected spinal-cord compression, severe infection, breathing/cardiac instability or another rapid deterioration.
Do not travel with incomplete basics
- No biopsy/pathology confirmation when it is still required
- No usable MRI or staging despite high-risk disease
- No clear treatment question
- No receiving department or appointment
Travel makes more sense when
- The diagnosis and risk group are documented
- The Chinese team has reviewed enough records to route the case
- A defined technology/second-opinion question exists
- The patient is medically stable to travel
How Parkmega Reviews a Prostate Cancer Case
Define risk and stage
We organize PSA, pathology, MRI/staging and previous-treatment history before choosing a hospital.
Identify the decision
Surgery vs radiation, HIFU, particle therapy, salvage treatment and mCRPC are different clinical questions.
Match the center
We compare disease-specific clinical strength with practical international access rather than using one “best hospital” list.
Confirm before travel
Ask for the department, likely tests, treatment route, estimate, expected stay and what still depends on in-person evaluation.
Send PSA, MRI and Biopsy Before Choosing a Hospital in China
We’ll identify whether the case is surveillance-, surgery-, radiation-, focal-treatment- or systemic-treatment focused, then compare the relevant Chinese hospital route before you make travel plans.
✓ Standard options compared first
✓ HIFU claims verified case by case
✓ No obligation to book
Related China Cancer Guides
Frequently Asked Questions
Direct answers to the prostate-cancer questions international patients most often ask before seeking care in China.
How is prostate cancer treated in China?
Treatment depends on risk group and stage. Options can include active surveillance, radical prostatectomy, external-beam radiation, brachytherapy, androgen-deprivation therapy, androgen-receptor pathway drugs, chemotherapy, targeted treatment for selected molecular findings, radiopharmaceutical treatment and clinical trials. HIFU and other focal approaches require careful selection and are not routine substitutes for standard curative treatment.
Can prostate cancer be cured in China?
Localized prostate cancer can often be treated with curative intent, but no hospital can guarantee a cure. The realistic question is whether the cancer is localized, locally advanced or metastatic, what the Grade Group and PSA show, and which standard treatment offers the best balance of cancer control and urinary, bowel and sexual side effects.
Which hospitals in China treat prostate cancer?
Relevant routes include Fudan University Shanghai Cancer Center for prostate oncology and advanced PSMA-based treatment, Shanghai Proton and Heavy Ion Center for particle-radiation evaluation, the National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences for urologic oncology and surgery, and Fuda Cancer Hospital for selected brachytherapy or local-treatment questions. International access should be confirmed for the exact center before travel.
Which hospitals in China use HIFU for prostate cancer?
HIFU is recognized in Chinese prostate-cancer guidance, but current hospital availability and international-patient access are center-specific. Public sources do not provide a reliable single nationwide list of foreign-patient HIFU programs. Ask a named hospital to confirm the device, focal or whole-gland approach, eligibility criteria, follow-up biopsies and whether treatment is offered within a registry or study.
Is HIFU a standard treatment for prostate cancer?
HIFU is a focal or whole-gland ablative technique, but major 2026 European guidance remains cautious and recommends focal or whole-gland ablative treatment mainly within clinical trials or registries because long-term comparative cancer-control data are still limited. It should be compared with active surveillance, surgery and radiation for the same risk group.
Is proton therapy available for prostate cancer in China?
Yes. Shanghai Proton and Heavy Ion Center treats prostate cancer within its particle-therapy program and has a published international-patient route. Proton or heavy-ion therapy is not automatically superior for every prostate-cancer patient, so the center should explain the expected benefit compared with modern photon radiotherapy.
What is the treatment for metastatic prostate cancer in China?
Metastatic hormone-sensitive prostate cancer is usually treated with androgen-deprivation therapy combined with additional systemic treatment selected for the patient, such as an androgen-receptor pathway inhibitor and, in some cases, chemotherapy. Treatment depends on disease volume, symptoms, previous therapy, age, comorbidity and molecular findings.
What treatments are available for castration-resistant prostate cancer in China?
Castration-resistant prostate cancer requires re-staging and review of previous therapies. Options may include androgen-receptor pathway drugs, chemotherapy, selected targeted therapies, bone-directed treatment, radiopharmaceutical approaches and clinical trials. In 2026, Fudan University Shanghai Cancer Center reported clinical use of Lu-177-PSMA radioligand therapy for selected PSMA-positive metastatic castration-resistant prostate cancer after prior treatment.
How much does prostate cancer treatment cost in China?
There is no credible universal package price. A diagnostic review, robotic prostatectomy, external-beam radiotherapy, seed brachytherapy, particle therapy and advanced systemic treatment have different cost structures. Ask for a written estimate after the hospital has reviewed PSA, MRI, biopsy pathology, staging and previous treatment.
When should a prostate cancer patient not fly to China for treatment?
Do not delay urgent local care for acute urinary retention, uncontrolled bleeding, severe uncontrolled pain, new leg weakness or numbness, loss of bladder or bowel control, severe infection, unstable heart or lung disease, or another acute deterioration. Travel should also wait when the diagnosis or staging is so incomplete that the receiving hospital cannot identify a treatment pathway.
Sources and Verification
- European Association of Urology (EAU) — Prostate Cancer Treatment Guidelines, current 2026 web version. Stage/risk-based treatment, radical prostatectomy, radiation, brachytherapy, focal therapy/HIFU caution, salvage treatment and CRPC framework. EAU Prostate Cancer — Treatment.
- EAU Patient Information — Focal and specialised treatments, updated February 2026. Patient-facing evidence caution for HIFU/focal therapy and the importance of risk group, long-term control and study/registry context. EAU Patient Information — Focal Treatments.
- US National Cancer Institute (NCI) — Prostate Cancer Treatment (PDQ). Standard treatment categories including surveillance, surgery, radiation, hormone therapy, chemotherapy, targeted therapy and radiopharmaceutical therapy. NCI Prostate Cancer Treatment.
- NCI — Hormone Therapy for Prostate Cancer. Current framework for treatment intensification in metastatic hormone-sensitive prostate cancer. NCI Hormone Therapy Fact Sheet.
- National Health Commission / Cancer Hospital, Chinese Academy of Medical Sciences — Chinese prostate cancer guideline (2022 edition). China-specific discussion of HIFU, salvage use and other focal/ablative techniques with long-term evidence limitations. Chinese Prostate Cancer Diagnosis and Treatment Guideline.
- Fudan University Shanghai Medical College — February 2026. Current report on Lu-177-PSMA radioligand therapy at Fudan University Shanghai Cancer Center for selected PSMA-positive metastatic castration-resistant prostate cancer; also cites National Cancer Center data for approximately 134,000 new prostate-cancer cases in China in 2022. FUSCC Prostate Cancer Radioligand Therapy.
- Fudan University Shanghai Medical College — FUSCC research-hospital update, June 2026. Current institutional status and development of Fudan University Shanghai Cancer Center as a National Cancer Medical Center / research hospital. FUSCC 2026 Institutional Update.
- Shanghai Proton and Heavy Ion Center — 10-year clinical report, May 2025. Prostate cancer is listed among the center’s major particle-radiation disease groups; outcome figures in that report are hospital-published cohort data and are not used here as individual predictions. Shanghai Proton and Heavy Ion Center 10-year Report.
- Shanghai Municipal Commission of Health — Shanghai Proton and Heavy Ion Center international profile. Current public international-service address, English/Japanese/German service, contact numbers and direct-pay insurer information. SPHIC International Profile.
- National Cancer Center / Cancer Hospital Chinese Academy of Medical Sciences — Urology Department. Official department profile documenting prostate-cancer diagnosis/treatment, robotic/laparoscopic surgery, nerve-preserving prostatectomy, MDT and clinical-trial activity. CAMS Cancer Hospital Urology.
- Beijing Municipal Government — Medical Guide for Foreigners in Beijing. Current foreign-patient appointment and payment framework for Beijing hospitals; exact CAMS overseas routing should still be reconfirmed with the hospital. Beijing Medical Guide for Foreigners.
- Guangzhou Fuda Cancer Hospital — Brachytherapy. Hospital-published description of iodine-125 seed implantation listing prostate cancer among potential indications. Fuda Brachytherapy.
- Guangzhou Fuda Cancer Hospital — International Contacts. Current foreign-patient contact routes and two Guangzhou campuses. Fuda International Contact.
Evidence rule: standard prostate-cancer treatment is grounded in current international guidance. China-specific technology and hospital claims are labeled by source. HIFU availability is treated as center-specific; a marketing claim is not accepted as proof that a foreign patient is eligible.
Last evidence check: September 2026. Hospital access, HIFU programs, radioligand availability, drug approvals, specialist schedules and costs can change; reconfirm before travel.
Get the Risk Group and Treatment Question Right Before You Travel
Send PSA history, biopsy pathology, prostate MRI/DICOM, staging and prior treatment. We’ll identify whether the useful China question is surgery, radiation, HIFU/focal therapy, particle therapy, recurrence management or advanced systemic/PSMA treatment.